Literature DB >> 27988092

Safety of Tranexamic Acid in Pediatric Cardiac Surgery: A Nationwide Database Study.

Takuma Maeda1, Yusuke Sasabuchi2, Hiroki Matsui3, Yoshihiko Ohnishi4, Shigeki Miyata5, Hideo Yasunaga3.   

Abstract

OBJECTIVES: The present study aimed to examine the association between tranexamic acid (TXA) use and adverse effects (seizures, thromboembolism, and renal dysfunction) in a pediatric cardiac surgery population using a national inpatient database in Japan. The authors also assessed the association between TXA use and other clinical outcomes (length of hospital stay and in-hospital mortality).
DESIGN: A nationwide, retrospective cohort study using propensity score analyses.
SETTING: Japanese Diagnosis Procedure Combination inpatient database. PARTICIPANTS: Pediatric patients who underwent cardiac surgery using cardiopulmonary bypass between July 2010 and March 2014 (N = 11,275).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Propensity-score matching created 3,739 pairs of patients with and without TXA administration. Propensity-matched analysis showed that the proportion of seizures was significantly higher in the TXA group than in the non-TXA group (1.6% v 0.2%, difference, 1.4%; 95% confidence interval, 1.0-1.9; p<0.001). However, none of the other outcomes was significantly different between the groups.
CONCLUSIONS: TXA use is associated with a significantly increased risk of seizures. However, there is no difference in any other outcomes between the TXA and non-TXA groups.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  mortality; pediatric cardiac surgery; seizure; tranexamic acid

Mesh:

Substances:

Year:  2016        PMID: 27988092     DOI: 10.1053/j.jvca.2016.10.001

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  7 in total

Review 1.  Antifibrinolytic Therapy and Perioperative Considerations.

Authors:  Jerrold H Levy; Andreas Koster; Quintin J Quinones; Truman J Milling; Nigel S Key
Journal:  Anesthesiology       Date:  2018-03       Impact factor: 7.892

2.  Pediatric Perioperative Clinical Pharmacy Practice: Clinical Considerations and Management: An Opinion of the Pediatrics and Perioperative Care Practice and Research Networks of the American College of Clinical Pharmacy.

Authors:  Elizabeth J Beckman; Sara Hovey; Deborah S Bondi; Gourang Patel; Richard H Parrish
Journal:  J Pediatr Pharmacol Ther       Date:  2022-08-19

3.  Tranexamic Acid Dosing in Craniosynostosis Surgery: A Systematic Review with Meta-analysis.

Authors:  Devon B O'Donnell; Sima Vazquez; Jacob D Greisman; Anaz Uddin; Gillian Graifman; Jose F Dominguez; Elizabeth Zellner; Carrie R Muh
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-10-17

Review 4.  Cerebrovascular Complications of Pediatric Blunt Trauma.

Authors:  Maria M Galardi; Jennifer M Strahle; Alex Skidmore; Akash P Kansagra; Kristin P Guilliams
Journal:  Pediatr Neurol       Date:  2020-01-11       Impact factor: 3.372

5.  Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study.

Authors:  Erika R O'Neil; Lindsay R Schmees; Karla Resendiz; Henri Justino; Marc M Anders
Journal:  Crit Care Explor       Date:  2020-01-29

6.  Safety and efficacy of tranexamic acid in paediatric cardiac surgery: study protocol for a double-blind randomised controlled trial.

Authors:  Yu Zhang; Yuan Jia; Jia Shi; Su Yuan; Rong Wang; Zhe Zhang; Xu Wang; Jinping Liu; Jun Ran; Yuchen Zhao; Zhongdong Hua; Jun Yan; Shoujun Li; Zhe Zheng; Shengshou Hu; Yang Wang; Fuxia Yan
Journal:  BMJ Open       Date:  2019-11-25       Impact factor: 2.692

7.  Evaluation of the safety of tranexamic acid use in pediatric patients undergoing spinal fusion surgery: a retrospective comparative cohort study.

Authors:  Iryna Ivasyk; Abhinaba Chatterjee; Catherine Jordan; Matthew T Geiselmann; Peter S Chang; Hooman Kamel; Sariah Khormaee
Journal:  BMC Musculoskelet Disord       Date:  2022-07-08       Impact factor: 2.562

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.